Superior Tumor Detection for<sup>68</sup>Ga-FAPI-46 Versus<sup>18</sup>F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma

Kim M. Pabst(Klinik und Poliklinik für Nuklearmedizin), Wolfgang P. Fendler(Essen University Hospital), Stefan Kasper(Essen University Hospital), Benedikt M. Schaarschmidt(Essen University Hospital), Hartmut Schmidt(Université Paris-Sud), Robert Seifert(University Hospital Münster), Simone Ballke(Technical University of Munich), Marija Trajkovic‐Arsic(German Cancer Research Center), Michael A. Nader(Essen University Hospital), Phyllis F. Cheung(German Cancer Research Center), Katharina Lueckerath(German Cancer Research Center), Lukas Kessler(German Cancer Research Center), Jens T. Siveke(German Cancer Research Center), Nader Hirmas(Deutsches Konsortium für Translationale Krebsforschung), Rainer Hamacher(Technical University of Munich), Aleksandar Milošević(Essen University Hospital), Katja Steiger(Technical University of Munich), Timo Bartel(Essen University Hospital), Ken Herrmann(Klinikum rechts der Isar)
Journal of Nuclear Medicine
April 6, 2023
10.2967/jnumed.122.265215
Cited by 63

Related Papers

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464